Cargando…
Two-stage optimal designs with survival endpoint when the follow-up time is restricted
BACKGROUND: Survival endpoint is frequently used in early phase clinical trials as the primary endpoint to assess the activity of a new treatment. Existing two-stage optimal designs with survival endpoint either over estimate the sample size or compute power outside the alternative hypothesis space....
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448233/ https://www.ncbi.nlm.nih.gov/pubmed/30943896 http://dx.doi.org/10.1186/s12874-019-0696-x |
_version_ | 1783408659010682880 |
---|---|
author | Shan, Guogen Zhang, Hua |
author_facet | Shan, Guogen Zhang, Hua |
author_sort | Shan, Guogen |
collection | PubMed |
description | BACKGROUND: Survival endpoint is frequently used in early phase clinical trials as the primary endpoint to assess the activity of a new treatment. Existing two-stage optimal designs with survival endpoint either over estimate the sample size or compute power outside the alternative hypothesis space. METHODS: We propose a new single-arm two-stage optimal design with survival endpoint by using the one-sample log rank test based on exact variance estimates. This proposed design with survival endpoint is analogous to Simon’s two-stage design with binary endpoint, having restricted follow-up. RESULTS: We compare the proposed design with the existing two-stage designs, including the two-stage design with survival endpoint based on the nonparametric Nelson-Aalen estimate, and Simon’s two-stage designs with or without interim accrual. The new design always performs better than these competitors with regards to the expected total study length, and requires a smaller expected sample size than Simon’s design with interim accrual. CONCLUSIONS: The proposed two-stage minimax and optimal designs with survival endpoint are recommended for use in practice to shorten the study length of clinical trials. |
format | Online Article Text |
id | pubmed-6448233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64482332019-04-15 Two-stage optimal designs with survival endpoint when the follow-up time is restricted Shan, Guogen Zhang, Hua BMC Med Res Methodol Research Article BACKGROUND: Survival endpoint is frequently used in early phase clinical trials as the primary endpoint to assess the activity of a new treatment. Existing two-stage optimal designs with survival endpoint either over estimate the sample size or compute power outside the alternative hypothesis space. METHODS: We propose a new single-arm two-stage optimal design with survival endpoint by using the one-sample log rank test based on exact variance estimates. This proposed design with survival endpoint is analogous to Simon’s two-stage design with binary endpoint, having restricted follow-up. RESULTS: We compare the proposed design with the existing two-stage designs, including the two-stage design with survival endpoint based on the nonparametric Nelson-Aalen estimate, and Simon’s two-stage designs with or without interim accrual. The new design always performs better than these competitors with regards to the expected total study length, and requires a smaller expected sample size than Simon’s design with interim accrual. CONCLUSIONS: The proposed two-stage minimax and optimal designs with survival endpoint are recommended for use in practice to shorten the study length of clinical trials. BioMed Central 2019-04-03 /pmc/articles/PMC6448233/ /pubmed/30943896 http://dx.doi.org/10.1186/s12874-019-0696-x Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Shan, Guogen Zhang, Hua Two-stage optimal designs with survival endpoint when the follow-up time is restricted |
title | Two-stage optimal designs with survival endpoint when the follow-up time is restricted |
title_full | Two-stage optimal designs with survival endpoint when the follow-up time is restricted |
title_fullStr | Two-stage optimal designs with survival endpoint when the follow-up time is restricted |
title_full_unstemmed | Two-stage optimal designs with survival endpoint when the follow-up time is restricted |
title_short | Two-stage optimal designs with survival endpoint when the follow-up time is restricted |
title_sort | two-stage optimal designs with survival endpoint when the follow-up time is restricted |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448233/ https://www.ncbi.nlm.nih.gov/pubmed/30943896 http://dx.doi.org/10.1186/s12874-019-0696-x |
work_keys_str_mv | AT shanguogen twostageoptimaldesignswithsurvivalendpointwhenthefollowuptimeisrestricted AT zhanghua twostageoptimaldesignswithsurvivalendpointwhenthefollowuptimeisrestricted |